Beacon Biosignals and Takeda have expanded their collaboration to progress narcolepsy diagnosis and the discovery of neurobiomarkers.
In 2024, Beacon Biosignals revealed a partnership with Takeda focused on at-home sleep monitoring for trials related to sleep disorders, utilising Beacon’s neurophysiology platform, including Dreem 3S EEG headband, AI-driven analytics, and clinico-EEG database.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The latest multi-year agreement will use the Beacon Platform to expedite sleep biomarkers and pattern development, aiming to support new diagnostic approaches and close care gaps for individuals with narcolepsy.
Beacon Biosignals will obtain up to $109m in data licence fees, milestone payments linked to development, regulatory, and commercial achievements, along with equity participation.
The collaboration utilises Waveband, Beacon’s at-home EEG headband, which is cleared by the US Food and Drug Administration, and AI algorithms to potentially reduce the diagnostic journey for those with narcolepsy.
The headband is capable of delivering polysomnography (PSG)-quality sleep staging across both clinical care settings and Phase I to Phase IV trials.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBeacon Biosignals co-founder and CEO Dr Jacob Donoghue said: “This collaboration demonstrates exactly what the Beacon Platform was purpose-built to do — enable earlier, more accurate diagnosis for patients and identify brain biomarkers that can guide the next generation of central nervous system (CNS) drug development.”
Takeda will utilise Beacon’s real-world clinical database to detect biomarkers of sleep and create new insights into the function of the brain.
The aim is to expedite discovery, enhance trial design, and expand therapeutic opportunities.
Narcolepsy is a neurological disorder that affects the brain’s ability to regulate sleep and wakefulness.
The condition is categorised into two types. Narcolepsy type one (NT1) occurs from a loss of orexin-producing neurons and results in daytime sleepiness, cataplexy, and disrupted night-time sleep. In narcolepsy type two (NT2), orexin levels remain generally normal.
Beacon Biosignals recently raised $86m in a Series B funding round to expand its neurodiagnostic dataset and further the clinical application of AI-driven brain health biomarkers.
